Figure 3.

Anti-PD-1 treatment caused no significant increase in liver toxicity as compared to vehicle control. Serum assessment for hepatic toxicities was performed by measuring AST and ALT. Significant difference was seen on ANOVA analysis between the treatment groups, though this is likely a result of the elevated LFTs caused by tissue damage by the tumor in the vehicle control and 1.0 mg/kg TV groups rather than administration of the anti-PD-1 antibody. The elevations in these two groups suggests that the LFT elevation is a result of increased tumor burden when correlated with the bioluminescence data.